	US 11,744,855 B2
	Nanodiamonds as artificial proteins for regulation of a cell signalling system
Petr Cigler, Prague (CZ); Lukas Balek, Klimkovice (CZ); Jan Havlik, Znojmo (CZ); Pavel Krejci, Brno (CZ); Lukas Trantirek, Brno (CZ); and Silvie Trantirkova, Brno (CZ)
Assigned to USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I, Prague (CZ); MASARYKOVA UNIVERZITA, Brno (CZ); and FAKULTNI NEMOCNICE U SV, ANNY V BRNE, Brno (CZ)
Appl. No. 16/981,578
Filed by USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., Prague (CZ); MASARYKOVA UNIVERZITA, Brno (CZ); and FAKULTNI NEMOCNICE U SV. ANNY V BRNE, Brno (CZ)
PCT Filed Mar. 26, 2019, PCT No. PCT/EP2019/057649 § 371(c)(1), (2) Date Sep. 16, 2020, PCT Pub. No. WO2019/185667, PCT Pub. Date Oct. 3, 2019.
Claims priority of application No. 18165299 (EP), filed on Mar. 30, 2018.
Prior Publication US 2021/0015856 A1, Jan. 21, 2021
Int. Cl. A61K 33/44 (2006.01); A61K 9/14 (2006.01); A61K 45/06 (2006.01); C07K 14/50 (2006.01)

CPC A61K 33/44 (2013.01) [A61K 9/14 (2013.01); A61K 45/06 (2013.01); C07K 14/50 (2013.01)]

9 Claims

1. A method of treatment of a disease caused by aberrant FGF-FGFR signaling and/or aberrant FGF-FGFR interaction, consisting of administration of nanodiamonds having a positive ζ-potential of at least 1 mV to a subject in need of such treatment,

wherein the disease caused by the aberrant FGF-FGFR signaling and/or aberrant FGF-FGFR interaction is selected from developmental defects and metabolic disorders,

wherein metabolic disorders do not include cancer.